CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 34 enrolled
Drug / intervention
Frequently Sampled Oral Glucose Tolerance Test and CGM +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03961516
NCT03961516N/ACompleted
CompareCT.gov

Glycemic Characterization and Pancreatic Imaging Correlates in Cystic Fibrosis

University Hospitals Cleveland Medical Center·observational·Posted May 23, 2019·Updated May 20, 2022

In Brief

An observational study evaluating Frequently Sampled Oral Glucose Tolerance Test and CGM and MRI Pancreas and Liver for Cystic Fibrosis and 4 related conditions. Completed, enrolled 34 participants across 1 site.

Detailed Summary

The purpose of this study is to investigate the utility of a continuous glucose monitor device (CGM) in screening for cystic fibrosis related diabetes. The investigators will also study how fat deposition in the pancreas and liver impacts insulin production and response, as measured by a frequently sampled oral glucose tolerance test.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsCystic Fibrosis, Cystic Fibrosis-related Diabetes, Cystic Fibrosis Liver Disease, Pancreatic Steatosis, Hepatic Steatosis
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
2020202120222023202420252026
First PostedMay 23, 2019
Enrollment StartMay 1, 2019
Primary CompletionAug 30, 2021
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 7.1 years ago

Interventions

Frequently Sampled Oral Glucose Tolerance Test and CGMdevice

Patients will undergo a 2 hour frequently sampled oral glucose tolerance test while wearing an active FreeStyle Libre Pro sensor. Using as a tool to collect data.

MRI Pancreas and Liverradiation

Patients will undergo an MRI of the pancreas and liver